



Stabilis



Nitroprusside sodium



Noms commerciaux

Nipride	Canada, Pays bas
Nipruss	Allemagne, Egypte
Nitropress	Etats Unis d'Amérique, Iran, Nouvelle Zélande
Nitroprussiate FID	France



Stabilité des solutions

		0,05 & 0,1 mg/ml	25°C		48			1037
	RL	0,05 & 0,1 mg/ml	25°C		48			1037
		0,05 & 0,1 mg/ml	25°C		48			1037
	RL	0,05 & 0,1 mg/ml	25°C		48			1037
		0,001 mg/ml	20°C		264			2028
		0,001 mg/ml	4°C		264			2028
		0,5 & 1,67 mg/ml	25°C		12			633
		1 mg/ml	25°C		24			196
		1 mg/ml	4°C		9			3903



Stabilité en mélange

		0,2 mg/ml	?		Dobutamine hydrochloride : 2 mg/ml Nitroglycerin : 0,2 mg/ml	24		1109
		1,2 mg/ml	22°C		Dobutamine hydrochloride : 5 mg/ml	24		3381

		0,4 mg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4		813
PVC	 	0,05 & 0,4 mg/ml	?		Ranitidine hydrochloride : 0,05 & 2 mg/ml	48		210
PE		1,2 mg/ml	22°C		Dobutamine hydrochloride : 5 mg/ml	24		3381
		0,18 mg/ml	25°C		Sodium thiosulfate : 1,8 mg/ml	48		4020
		0,2 mg/ml	15-30°C		Esmolol hydrochloride : 10 mg/ml	24		363
		0,18 mg/ml	25°C		Sodium thiosulfate : 1,8 mg/ml	48		4020



Facteur influençant la stabilité

				196
				1151
				1316
				1379
				3177
				3381



Compatibilités

	Nitroprusside sodium : 0,4 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
	Nitroprusside sodium : 0.2 mg/ml Argatroban : 1 mg/ml		1963
	Nitroprusside sodium : 0.2 mg/ml Atracurium besylate : 0.5 mg/ml		402
	Nitroprusside sodium : 2 mg/ml Bivalirudin : 5 mg/ml		1713
	Nitroprusside sodium : 25 mg/ml Caffeine : 10 mg/ml		3964
	Nitroprusside sodium : 0.4 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	 	4528
	Nitroprusside sodium : 0.4 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml	 	3828
	Nitroprusside sodium : 0.5 mg/ml Cimetidine hydrochloride : 3 mg/ml		1201
	Nitroprusside sodium : 2 mg/ml Cisatracurium besylate : 0.1 mg/ml		299
			299
	Nitroprusside sodium : 25 mg/ml Cloxacillin sodium : 100 mg/ml		3012
	Nitroprusside sodium : 2 mg/ml Dexmedetomidine : 4 µg/ml		1712
	Nitroprusside sodium : 0.2 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198

	Nitroprusside sodium : 1,2 mg/ml Dobutamine hydrochloride : 5 mg/ml		3177	
	Nitroprusside sodium : 1.2 mg/ml Dobutamine hydrochloride : 5 mg/ml		2879	
	Nitroprusside sodium : 1.2 mg/ml Dopamine hydrochloride : 5 mg/ml		3381	
	Nitroprusside sodium : 0.2 mg/ml Enalaprilate : 0.05 mg/ml		1315	
	Nitroprusside sodium : 0,91 mg/ml Enalaprilate : 0,011 mg/ml		963	
	Nitroprusside sodium : 0,2 mg/ml Esmolol hydrochloride : 10 mg/ml		363	
	Nitroprusside sodium : 0.2 mg/ml Famotidine : 0.2 mg/ml		398	
	Nitroprusside sodium : 2 mg/ml Fenoldopam mesylate : 80 µg/ml		1803	
	Nitroprusside sodium : 0.4 mg/ml Fosfomycin : 30 mg/ml		4055	
		Nitroprusside sodium : 0.2 mg/ml Haloperidol lactate : 5 mg/ml		403
	Nitroprusside sodium : 0.2 mg/ml Heparin sodium : 100 UI/ml		295	
	Nitroprusside sodium : 25 mg/ml	RL	4603	
	Nitroprusside sodium : 0.4 mg/ml		1415	
	Nitroprusside sodium : 0.2 mg/ml Heparin sodium : 50 UI/ml		317	
	Nitroprusside sodium : 0.4 mg/ml		301	
	Nitroprusside sodium : 0.2 mg/ml Haloperidol lactate : 0.5 mg/ml		403	
	Nitroprusside sodium : 2 mg/ml Hetastarch : 60 mg/ml		1721	
	Nitroprusside sodium : 0.2 mg/ml Indomethacin sodium trihydrate : 1 mg/ml		467	
	Nitroprusside sodium : 0.2 mg/ml Insulin : 1 UI/ml		295	
	Nitroprusside sodium : 1,25 mg/ml Insulin aspart : 1 UI/ml		1508	
	Nitroprusside sodium : 0.4 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829	
	Nitroprusside sodium : 0.2 mg/ml Labetalol hydrochloride : 5 mg/ml		295	
		Nitroprusside sodium : 10 mg/ml Levofloxacin : 5 mg/ml		1072
	Nitroprusside sodium : 25 mg/ml Meropenem : 50 mg/ml		4319	
	Nitroprusside sodium : 0.4 mg/ml Metoprolol tartrate : 1 mg/ml		2346	
	Nitroprusside sodium : 2 mg/ml Micafungin : 1.5 mg/ml		2108	
	Nitroprusside sodium : 0.2 mg/ml Midazolam hydrochloride : 1 mg/ml		295	

		Nitroprusside sodium : 0,2 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Nitroprusside sodium : 1.6 mg/ml Milrinone lactate : 0.8 mg/ml		813
		Nitroprusside sodium : 0.2 mg/ml Morphine sulfate : 1 mg/ml		295
		Nitroprusside sodium : 10 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Nitroprusside sodium : 0.2 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Nitroprusside sodium : 0.4 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Nitroprusside sodium : 0.2 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Nitroprusside sodium Pantoprazole sodium		2090
		Nitroprusside sodium : 0.4 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Nitroprusside sodium : 0.4 mg/ml Propofol : 10 mg/ml		300
		Nitroprusside sodium : 0.05 & 0.4 mg/ml Ranitidine hydrochloride : 0.05 & 2 mg/ml		214
		Nitroprusside sodium : 10 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Nitroprusside sodium : 1.2 mg/ml Sodium thiosulfate : 10 mg/ml		3381
		Nitroprusside sodium : 0.2 mg/ml Sodium thiosulfate : 2 mg/ml		4020
		Nitroprusside sodium : 12 mg/ml Sugammadex : 100 mg/ml		3372
		Nitroprusside sodium : 0,004 mg/ml Tacrolimus : 1000 µg/ml		479
		Nitroprusside sodium : 0.2 mg/ml Theophylline : 4 mg/ml		317
		Nitroprusside sodium : 10 mg/ml Thiopental sodium : 25 mg/ml		3767
		Nitroprusside sodium : 0.2 mg/ml Vecuronium bromide : 0.1 mg/ml		402
		Nitroprusside sodium : 0.1 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057



Voie d'administration





Bibliographie

	Type	Source
176	Revue	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
196	Revue	Pramar Y, Das Gupta V, Neal Gardner S, Yau B. Stabilities of dobutamine, dopamine, nitroglycerin and sodium nitroprusside in disposable plastic syringes. J Clin Pharm Ther 1991 ; 16: 203-207.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
210	Revue	Stewart JT, Warren FW, King AD. Stability of ranitidine hydrochloride and seven medications. Am J Hosp Pharm 1994 ; 51: 1802-1807.
214	Revue	Galante LJ, Stewart JT, Warren FW, Edgar JW, Huff AJ. Stability of ranitidine hydrochloride with eight medications in intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 1606-1610.
295	Revue	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
363	Revue	Karnatz NN, Wong J, Baaske DM, Johnson JH, Speicher ER, Herbranson DE. Stability of esmolol hydrochloride and sodium nitroprussiate in intravenous admixtures. Am J Hosp Pharm 1989 ; 46: 101-104.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
403	Revue	Outman WR, Monolakis J. Visual compatibility of haloperidol lactate with 0.9% sodium chloride injection or injectable critical-care drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 1539-1541.
467	Revue	Ishisaka DY, van Vleet J, Marquardt E. Visual compatibility of indomethacin sodium trihydrate with drugs given to neonates by continuous infusion. Am J Hosp Pharm 1991 ; 48: 2442-2443.

479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
633	Revue	Sewell GJ, Forbes DR, Munton TJ. The stability of sodium nitroprusside infusion during administration by motorized syringe-pump. J Clin Hosp Pharm 1985 ; 10: 351-360.
813	Revue	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
963	Revue	Schaaf LJ, Tremel LC, Wulf BG, Vernon KK. Compatibility of enalaprilat with dobutamine, dopamine, heparin, nitroglycerin, potassium chloride and nitroprusside. J Clin Pharm Ther 1990 ; 15: 371-376.
1037	Revue	Mahony C, Brown JE, Stargel WW, Verghese CP, Bjornsson TD. In vitro stability of sodium nitroprusside solutions for intravenous administration. J Pharm Sci 1984 ; 73: 838-839.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1072	Revue	Saltzman CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459.
1109	Revue	Horror JC, Digregorio J, Barbieri EJ, Rupp E. Intravenous infusions of nitroprusside, dobutamine, and nitroglycerin are compatible. Crit Care Med 1990 ; 18: 858-861.
1151	Revue	Baaske DM, Smith MD, Karnatz N, Carter JE. High-performance liquid chromatographic determination of sodium nitroprusside. J Chromatogr 1981 ; 212: 339-346.
1201	Revue	Yuhaz EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1316	Revue	Davidson SW, Lyall D. Sodium nitroprusside stability in light-protective administration sets. Pharm J 1987 ; 239: 599-601.
1379	Revue	Saunders A. Stability and light sensitivity of sodium nitroprusside infusions. Aust J Hosp Pharm 1986 ; 16: 55-56.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1508	Revue	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.

1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1963	Revue	Honisko ME, Fink JM, Militello MA, Mauro VF, Alexander KS. Compatibility of argatroban with selected cardiovascular agents. Am J Health-Syst Pharm 2004 ; 61: 2415-2418.
2028	Revue	Kaiserlian CE, Razzouq N, Astier A, Paul M. Sodium nitroprusside stability at 1 µg/ml in aqueous solutions. EJHP Science 2005 ; 11, 4: 88-90.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2346	Revue	Newland A.M, Mauro V.F, Alexander K.S. Physical compatibility of metoprolol tartrate injection with selected cardiovascular agents Am J Health-Syst Pharm 2009 ; 66: 986-987.
2879	Poster	Imesch G., Humbert-Delaloye V., Berger M., Pannatier A. Compatibilité entre amiodarone, catecholamines et/ou nitroprussiate de sodium, administré en continu par voie veineuse aux soins intensifs adultes. GSASA Congress - Lucerne - Switzerland 2008
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3177	Poster	Humbert-Delaloye V, Berger M, Pannatier A. Compatibilités physico-chimique entre catécholamines, amiodarone, et/ou nitroprussiate de sodium intraveineux. 16èmes JFSPH, Sion, 18-19 novembre 2010 2010
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3381	Revue	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Gattlen L, Pannatier A. In vitro compatibility of various cardioactive drugs during simulated Y-site administration. EJHP 2013 ; 20:110-116.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.

3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3903	Revue	Anderson Collin R, Collins D, Laursen T, Arave T, Helm M. Stability of Sodium Nitroprusside in 5% Dextrose Stored at 4°C in Polypropylene Syringes Protected from Light. Int J Pharm Compound 2016 ; 20, 5 : 435-437.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4020	Revue	T. Schulz L, J. Elder E, Jones K, Vijayan A, D. Johnson B, E. Medow J, Vermeulen L. Stability of Sodium Nitroprusside and Sodium Thiosulfate 1:10 Intravenous Admixture. Hosp Pharm 2010 ;45,10:779?784
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.



Dictionnaire

	Vasodilatateur		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Verre
	NaCl 0,9% ou glucose 5%		A l'abri de la lumière
	Heure	RL	Ringer lactate
	Polyvinyl chlorure		Seringue polypropylène
	Glucose 5%		Jour
	Stabilité en mélange		Solvant
	Molécule		Chlorure de sodium 0,9%
	Non précisée		Polyéthylène
	Non précisé		Facteur influençant la stabilité
	Lumière		Provoque
	Dégradation		Compatibilités
	Compatible		Aucun
	Précipitation immédiate		Incompatible
	Eau pour préparation injectable		Nutrition parentérale (mélange ternaire)
	Nutrition parentérale (mélange binaire)		Solvant spécifique
	Turbidité immédiate		Précipitation en 15 minutes
	Changement de couleur en 24 heures		Voie d'administration
	Perfusion continue		Bibliographie
	Dictionnaire		